Neurocrine

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.

About NBIX

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. 

CEO
Kyle W. Gano
CEOKyle W. Gano
Employees
1,800
Employees1,800
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1992
Founded1992
Employees
1,800
Employees1,800

NBIX Key Statistics

Market cap
12.67B
Market cap12.67B
Price-Earnings ratio
42.62
Price-Earnings ratio42.62
Dividend yield
Dividend yield
Average volume
913.91K
Average volume913.91K
High today
$129.27
High today$129.27
Low today
$126.20
Low today$126.20
Open price
$126.20
Open price$126.20
Volume
924.69K
Volume924.69K
52 Week high
$157.98
52 Week high$157.98
52 Week low
$84.23
52 Week low$84.23

NBIX News

TipRanks 1d
Neurocrine initiates Phase 1 study of NBIP-01435

Neurocrine (NBIX) Biosciences announced the initiation of a Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, pharma...

Analyst ratings

85%

of 27 ratings
Buy
85.2%
Hold
14.8%
Sell
0%

People also own

Based on the portfolios of people who own NBIX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.